Organon has signed an agreement with Eli Lilly and Company to secure the sole distribution and commercialisation right for the migraine medicines Emgality (galcanezumab) and Rayvow (lasmiditan) in Europe.

European Medicines Agency (EMA)-approved Emgality is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP).

Rayvow is an oral therapy designed to bind to 5-HT1F receptors with high affinity. It is also cleared by the EMA to treat the headache stage of migraine attacks, with or without aura in adults.

The deal expands the European product portfolio of US-based Organon, a healthcare company focused on women’s health.

Organon CEO Kevin Ali said: “This commercialisation agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our Established Brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine.

“Our strong commercial expertise and proven track record in this therapeutic area will help enable us to bring these important treatments to more patients across Europe who need them.”

Under the terms of the agreement, Lilly will remain the marketing authorisation holder and will produce Emgality and Rayvow for sale.

The total consideration that will be given to Lilly includes a $50m upfront payment as well as sales-based milestone payments.

The deal is anticipated to finalise in Q1 2024 after the necessary country-specific agencies have finished their review.

Eli Lilly and Company executive vice president and Lilly International president Ilya Yuffa said: “Lilly is committed to helping people living with migraine, a debilitating neurological disease.

“We are confident this collaboration with Organon will help even more people throughout Europe gain access to our innovative migraine treatments.”